-
Halozyme Achieves Endpoint In Pancreatic Cancer Study, But Not Everyone Is Bullish
Thursday, January 5, 2017 - 10:56am | 505Read More...Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company focused on developing and commercializing novel oncology products that target tumor microenvironment, gained more than 10 percent Thursday morning. Investors and traders were buying Halozyme's stock after the company...
-
Biotechs Struggling To Find A Bottom
Tuesday, April 8, 2014 - 10:24am | 971Read More...The great biotechnology sell-off of 2014 began on February 26 and started as big sell-offs often do: quietly. The SPDR S&P Biotechnology exchange-traded fund (NYSE: XBI) peaked at $172.52 and closed at $170.01, off 40 cents from the day before. The next day, the ETF finished at a record...
-
Market Wrap For April 4: Dow Suffers Triple Digit Point Loss, Nasdaq Continues To Underperform
Friday, April 4, 2014 - 4:44pm | 2444Read More...U.S. stocks ended the week on a sour note as investors continue to sell many momentum names. Not helping the bull case was the much anticipated Jobs report number which failed to "wow" the market, coming in relatively in-line with expectations. The Dow suffered a triple digit point loss and...
-
Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR)
Saturday, March 23, 2013 - 11:33am | 835Read More...Some smaller health care companies saw unusual movement in their stocks on Friday. And not just in Anacor Pharmaceuticals (NASDAQ: ANAC), Halozyme Therapeutics (NASDAQ: HALO), Puma Biotechnology (NYSE: PBYI) and Questcor Pharmaceuticals (NASDAQ: QCOR), which are discussed below. But also ACADIA...
-
Stifel Nicolaus Initiates Coverage on Halozyme Thearapeutics at Buy (HALO)
Friday, April 1, 2011 - 9:14am | 125Read More...Stifel Nicolaus is out with its report today on Halozyme Therapeutics (NASDAQ: HALO), initiating shares of HALO at Buy. In a note to clients, Stifel Nicolaus writes, "We are initiating coverage of Halozyme with a Buy rating on the shares and a $10 price target. In our opinion, Halozyme offers a...
-
Wedbush Says HALO Is "No Fallen Angel"
Wednesday, March 23, 2011 - 8:00am | 169Read More...In a report published by Wedbush, Halozyme Therapeutics (NASDAQ: HALO) has been under pressure, trading in the $6 range. Wedbush said that it sees 55-68% potential upside for the stock on the way to its $10 fair value estimate. “Maintaining our OUTPERFORM rating and our $10/share fair value. We...
-
Halozyme Reveals New Development Plans
Friday, October 15, 2010 - 8:22am | 156Read More...Oppenheimer has published a research report on Halozyme Therapeutics (NASDAQ: HALO) as the company reveals plans for new development programs. In the report, Oppenheimer writes "On 10/14, HALO hosted a well-attended R&D day focused on both the company's proprietary programs and partnered...
